Sir.—The article by Koskiniemi et al1 that appeared in the June 1989 issue of AJDC illustrates the great need for controlled data concerning optimal means to diagnose and treat congenital toxoplasmosis. We are conducting a randomized, prospective study to evaluate treatment and outcome of patients with congenital toxoplasmosis. This national collaborative study is supported by the National Institutes of Allergy and Infectious Diseases, the March of Dimes, and the Food and Drug Administration, Orphan Drugs Division.
Patients are stratified based on severity of their disease. They are then randomized to one of three treatment regimens, which include pyrimethamine, sulfonamides, folinic acid, and spiramycin.
To ensure uniform evaluation, patients are evaluated at the study center in Chicago, Ill, at ages 0 to 2 months and 1, 3.5, 5.5, 8, and 15 years. Evaluation includes assessments of the patient's immunologic response to Toxoplasma gondii and assessments by specialists in pediatric